Skip to main content
Log in

Osmotic fragility of drug carrier erythrocytes

  • Original Papers
  • Published:
Research in Experimental Medicine

Summary

Erythrocytes have been proposed as biogradable cellular carriers for drugs. Potentials of this therapeutic approach are organ-specific targeting, protection and prolonged in vivo function of the encapsulated drugs. Previous studies demonstrated the advantage of a hypo-osmotic dialysis procedure for macromolecule loading resulting in cells that are closely similar to normal erythrocytes. Osmotic fragility of unloaded and loaded “carrier” erythrocytes was studied both in respect of shelf-life and in vivo survival. Sudden haemolysis which is characteristic for normal erythrocytes was never obtained with carrier erythrocytes. Haemolysis appeared at all osmotic pressures and increased stepwise indicating the existence of various cell populations. However, the majority of cells were haemolysed at lower values of the osmotic fragility curve. Osmotic fragility was highly increased when cytotoxic chemotherapeutics were encapsulated, and these cells appeared as spherocytes using scanning electron microscopy. Osmotic fragility proved to be a simple but reliable method for the in vitro evaluation of carrier erythrocytes and the effect of the encapsulated substances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Castle WB, Daland GA (1937) Susceptibility of mammalian erythrocytes to haemolysis with hypotonic solution. Arch Int Med 60:949–966

    Google Scholar 

  2. Chang TMS (1978) Biomedical applications of immobilized enzymes and proteins. Academic Press, London

    Google Scholar 

  3. Dacie JV, Lewis SM (1968) Practical haematology, 4th edn. Churchill, London

    Google Scholar 

  4. Dale JV, Villacorte DG, Beutler E (1977) High-yield entrapment of proteins into erythrocytes. Biochem Med 18:220–225

    PubMed  Google Scholar 

  5. DeLoach JR, Ihler GM (1977) A dialysis procedure of loading erythrocytes with enzymes and lipids. Biochem Biophys Acta 496:136–145

    PubMed  Google Scholar 

  6. DeLoach JR, Barton C (1982) Circulating carrier erythrocytes: slow-release vehicle for antileukemic drug cytosine arabinoside. Am J Vet Res 43:2210–2212

    PubMed  Google Scholar 

  7. DeLoach JR, Barton C (1981) Glutaraldehyde-treated carrier erythrocytes for organ targeting of methotrexate in dogs. Am J Vet Res 42:1971–1974

    PubMed  Google Scholar 

  8. DeLoach JR, Wagner AA, Craig TM (1981) Almidocarb dipropionate encapsulation and binding to resealed carrier bovine erythrocytes for potential babesiosis chemotherapy. J Appl Biochem 3:254–262

    Google Scholar 

  9. Gregoriadis G (1979) Drug carriers in biology and medicine. Academic Press, London

    Google Scholar 

  10. Ham TH, Castle WB (1940) Studies on destruction of red blood cells. Proc Am Philos Soc 82:411–419

    Google Scholar 

  11. Hoffmann JF (1958) The physiological characteristics of human red blood cell ghosts. J Gen Physiol 42:9–16

    PubMed  Google Scholar 

  12. Hubbard AR, Sprandel U, Chalmers RA (1980) Organic acid transport in resealed haemoglobin containing human erythrocyte “ghosts.” Biochem J 190:653–658

    PubMed  Google Scholar 

  13. Ihler GM, Glew RH, Schnure FW (1973) Enzyme loading of erythrocytes. Proc Natl Acad Sci USA 70:2663–2666

    PubMed  Google Scholar 

  14. Sprandel U, Hubbard AR, Chalmers RA (1979) In vitro studies on resealed erythrocyte ghosts as protein carriers. Res Exp Med (Berl) 175:239–245

    Google Scholar 

  15. Sprandel U, Hubbard AR, Chalmers RA (1981) Towards enzyme therapy using carrier erythrocytes. J Inherited Metab Dis 4:99–100

    PubMed  Google Scholar 

  16. Sprandel U, Hubbard AR, Chalmers RA (1979) Membrane transport in resealed haemoglobin-containing human erythrocyte “ghosts” prepared by a dialysis procedure. Biochem Biophys Res Commun 91:79–85

    PubMed  Google Scholar 

  17. Sprandel U, Chalmers RA (1980) Morphologie von Erythrozytenschatten als in vivo-Trägersysteme. Verh Dtsch Ges Inn Med 86:1090–1092

    Google Scholar 

  18. Sprandel U, Hubbard AR, Chalmers RA (1980) Survival of “carrier” erythrocytes in dogs. Clin Sci 59:7–8

    PubMed  Google Scholar 

  19. Sprandel U, Hubbard AR, Chalmers RA (1981) In vivo-Überlebenszeit von Erythrozytenschatten als Trägersysteme für Pharmaka. Verh Dtsch Ges Inn Med 87:1172–1174

    Google Scholar 

  20. Weed AI, Reed CF (1966) Membrane alterations leading to red cell destruction. Am J Med 41:681–698

    PubMed  Google Scholar 

  21. Williams TF, Fordham CC, Hollander W, Welt LG (1959) Study of the osmotic behavior of the human erythrocyte. J Clin Invest 38:1587–1596

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sprandel, U., Zöllner, N. Osmotic fragility of drug carrier erythrocytes. Res. Exp. Med. 185, 77–85 (1985). https://doi.org/10.1007/BF01851531

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01851531

Key words

Navigation